Hikal shows 17% degrowth in Q1 FY23

Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore

IOL Chemicals and Pharmaceuticals reports Q1 FY23 revenue of Rs. 570.2 Cr

The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr

Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.

ShilpaMedicare Q1FY23 consolidated PAT drops to to Rs. 84.85 lakhs

Aurobindo Pharma posts consolidated Q1FY23 PAT of Rs. 520.54 Cr

The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.

Lincoln Pharmaceuticals Q1 FY23 consolidated profit up at Rs. 15.01 Cr

The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.

IPCA Laboratories Q1 FY23 consolidated PAT higher at Rs. 143.06 Cr

The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.

Max Healthcare Institute Q1 FY23 consolidated PAT soars at Rs. 172.83 Cr

The company has reported total income of Rs. 1097.78 crores during the period ended June 30, 2022.

Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr

The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.

Vijaya Diagnostic Centre Q1 FY23 revenue down 14.9%

EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%

Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr

The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.

Unichem Laboratories Q1 FY23 consolidated loss at Rs. 23.36 Cr

The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022

Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher

Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.

Fortis Healthcare posts Q1 FY2023 consolidated PAT at Rs. 122.25 Cr

The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.

Briefs: Zydus Lifesciences and Kimia Biosciences

The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.

Lyka Labs swings back to profit in Q1FY23

The company has reported total income of Rs. 28.20 crores during the period ended June 30, 2022.

Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr

The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.

JB Pharma records revenue growth of 30% in Q1 FY23

Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23

Ube to buy API Corp. from Mitsubishi Chemical

APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years

FDC Limited reports Q1 FY23 revenue growth of 10%

The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands